Like cartographers completing a map, investigators have identified multiple new subtypes of the most common childhood cancer—research that will likely improve the diagnosis and treatment of high-risk patients. St. Jude ...
Jan 14, 2019
0
25
University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential way to target a subtype of acute myeloid leukemia (AML) using chimeric antigen receptor (CAR) T-cell therapy, a form ...
Jan 4, 2019
0
2
Physician-scientists from Children's Hospital of Philadelphia (CHOP) presented updated efficacy and safety data on Kymriah(R) (tisagenlecleucel, formerly CTL019) —the first-ever U.S. Food and Drug Administration (FDA) approved ...
Dec 4, 2018
0
1
Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy (CAR-T cell therapy) in treating cancer. They are presenting results of their preclinical research ...
Dec 4, 2018
0
1
Adoptive cell transfer (ACT) is a promising cancer immunotherapy that involves isolating T cells from cancer patients that are capable of targeting their tumor, selecting the more active T cells and expanding those in the ...
Nov 29, 2018
0
36
Something as simple as a change in diet can potentially help to increase the cancer survival rate of obese children with acute lymphoblastic leukemia, the most common childhood cancer, according to a new study by UCLA scientists.
Oct 31, 2018
0
71
Children with pediatric acute lymphoblastic leukemia (ALL) gain weight during treatment, and researchers at St. Jude Children's Research Hospital have discovered that this problem starts during remission-induction treatment ...
Oct 26, 2018
0
0
A single leukemia cell, unknowingly engineered with the leukemia-targeting chimeric antigen receptor (CAR) lentivirus and infused back into a patient, was able to reproduce and cause a deadly recurrence of B-cell acute lymphoblastic ...
Oct 1, 2018
0
20
Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) were significantly more likely to relapse than pediatric ALL patients, and factors including lower clinical trial enrollment and shorter duration ...
Sep 27, 2018
0
1
Neonatal concentrations of eight detectable inflammatory markers were significantly different in children later diagnosed with B-cell precursor acute lymphoblastic leukemia (ALL) compared with controls.
Sep 14, 2018
0
0
